Key facts
- Aelius Biotech’s last known valuation is $3.1M (Nov 2023).
- It has raised $2.5M; the latest was Later Stage VC ($970K) in Apr 2025.
- Notable investors include Innovate UK, Mercia Ventures, European Regional Development Fund (Brandenburg), NEDFi Venture Capital, Newcastle University — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Aelius Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Aelius Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Aelius Biotech
Developer of a model gut system intended to help healthcare industry participants simulate digestion, mucus permeation, and epithelial absorption. The company offers a range of in vitro testing and in vivo testing, simple lab assays and routine testing, rheology, integrated model gut testing through the aerodigestive tract, and also runs human trials, enabling healthcare companies to make data-driven decisions to drive and develop and de-risk orally delivered products in development.
- Sector
- Healthcare
- HQ
- Newcastle upon Tyne, United Kingdom
- Founded
- 2018
- Employees
- 18
- Website
- aeliusbiotech.co.uk/
- Ownership
- Privately Held (backing)
Aelius Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aelius Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aelius Biotech in its N-PORT filings yet. We sweep new filings monthly.